Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness

Gynecologic Oncology

Volumn 132, Issue 2, 2014, Pages 287-291

  Da Costa Miranda, Vanessa ^a   De Souza Fêde, Ângelo Bezerra ^a   Dos Anjos, Carlos Henrique ^a   Da Silva, Juliana Ribeiro ^a   Sanchez, Fernando Barbosa ^a   Da Silva Bessa, Lyvia Rodrigues ^a   De Paula Carvalho, Jesus ^a   Filho, Elias Abdo ^a   De Freitas, Daniela ^a   Del Pilar Estevez Diz, Maria ^a  

^a Instituto do Câncer do Estado de 11São Paulo ICESP   (Brazil)

Author keywords

Carboplatin and paclitaxel; Neoadjuvant therapy; Ovarian cancer; Survival; Toxicity

Indexed keywords

CARBOPLATIN AND PACLITAXEL; NEOADJUVANT THERAPY; OVARIAN CANCER; SURVIVAL; TOXICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84894095209     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.12.002     Document Type: Article

References (19)

1. Site Globocan http://globocan.iarc.fr/ [acessado em 15/abril/2013]
2. R. Sankaranarayanan, and J. Ferlay Worldwide burden of gynaecological cancer: the size of the problem Best Pract Res Clin Obstet Gynaecol 20 2006 207
3. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74
4. R.C. Young, D.G. Decker, J.T. Wharton, M.S. Piver, W.F. Sindelar, and B.K. Edwards et al. Staging laparotomy in early ovarian cancer JAMA 250 22 1983 3072
5. I. Vergote, C.G. Tropé, and F. Amant Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 10 2010 943
6. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
7. P.E. Goss, B.L. Lee, T. Badovinac-Crnjevic, K. Strasser-Weippl, Y. Chavarri-Guerra, and J. St Louis et al. Planning cancer control in Latin America and the Caribbean Lancet Oncol. 14 2013 391 436
8. Y. Ansquer, E. Leblanc, and K. Clough Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study Cancer 91 12 2001 2329
9. S. Kang, and B.H. Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol 16 8 2009 2315
10. http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ ctcaev3.pdf
11. E. Kaplan Non parametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
12. D. Cox Regression models and life-tables J R Stat Soc Ser B 34 1972 187 220
13. C. Witlekind, C.C. CCampton, F.L. Greene, and L.H. Sobin TNM residual tumor classification revised Cancer 94 2002 2511 2519
14. R.F. Ozols, B.N. Bundy, and B.E. Greer J Clin Oncol 21 17 Sep 1, 2003 3194 3200
15. JCO 21 17 2003 3195 3200
16. M.M. Thrall, H.J. Gray, R.G. Symons, N.S. Weiss, D.R. Flum, and B.A. Goff Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer Gynecol Oncol 123 2011 461
17. R.E. Bristow, and D.S. Chi Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis Gynecol Oncol 103 3 2006 1070
18. G. Peter, and M.D. Rose Secondary surgical cytoreduction for advanced ovarian carcinoma N Engl J Med 351 2004 2489 2497
19. S. Kehoe, and J. Hook Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial J Clin Oncol 31 2013 [Suppl.;abstr 5500]